Ferrer Miguel D, Reynés Clara, Monserrat-Mesquida Margalida, Quetglas-Llabrés Magdalena, Bouzas Cristina, García Silvia, Mateos David, Casares Miguel, Gómez Cristina, Ugarriza Lucía, Tur Josep A, Sureda Antoni, Pons Antoni
Research Group in Community Nutrition and Oxidative Stress, University of the Balearic Islands-IUNICS, 07122 Palma de Mallorca, Spain.
Research Group in Community Nutrition and Oxidative Stress, Health Research Institute of Balearic Islands (IdISBa), 07120 Palma de Mallorca, Spain.
Antioxidants (Basel). 2023 Mar 13;12(3):711. doi: 10.3390/antiox12030711.
Hepatic fat accumulation is the hallmark of non-alcoholic fatty liver disease (NAFLD). Our aim was to determine the plasma levels of oxylipins, free polyunsaturated fatty acids (PUFA) and markers of lipid peroxidation in patients with NAFLD in progressive stages of the pathology. Ninety 40-60-year-old adults diagnosed with metabolic syndrome were distributed in without, mild, moderate or severe NAFLD stages. The free PUFA and oxylipin plasma levels were determined by the UHPLC-MS/MS system. The plasma levels of oxylipins produced by cyclooxygenases, lipoxygenases and cytochrome P450, such as prostaglandin 2α (PGF2α), lipoxinB4 and maresin-1, were higher in severe NAFLD patients, pointing to the coexistence of both inflammation and resolution processes. The plasma levels of the saturated oxylipins 16-hydroxyl-palmitate and 3-hydroxyl-myristate were also higher in the severe NAFLD patients, suggesting a dysregulation of oxidation of fatty acids. The plasma 12-hydroxyl-estearate (12HEST) levels in severe NAFLD were higher than in the other stages, indicating that the hydroxylation of saturated fatty acid produced by reactive oxygen species is more present in this severe stage of NAFLD. The plasma levels of 12HEST and PGF2α are potential candidate biomarkers for diagnosing NAFLD vs. non-NAFLD. In conclusion, the NAFLD progression can be monitored by measuring the plasma levels of free PUFA and oxylipins characterizing the different NAFLD stages or the absence of this disease in metabolic syndrome patients.
肝脂肪堆积是非酒精性脂肪性肝病（NAFLD）的标志。我们的目的是确定处于疾病进展阶段的NAFLD患者血浆中氧化脂质、游离多不饱和脂肪酸（PUFA）和脂质过氧化标志物的水平。90名年龄在40 - 60岁、被诊断患有代谢综合征的成年人被分为无NAFLD、轻度NAFLD、中度NAFLD或重度NAFLD阶段。通过超高效液相色谱 - 串联质谱系统测定游离PUFA和氧化脂质的血浆水平。在重度NAFLD患者中，由环氧化酶、脂氧合酶和细胞色素P450产生的氧化脂质血浆水平较高，如前列腺素2α（PGF2α）、脂oxinB4和maresin - 1，这表明炎症和炎症消退过程同时存在。重度NAFLD患者中饱和氧化脂质16 - 羟基 - 棕榈酸酯和3 - 羟基 - 肉豆蔻酸酯的血浆水平也较高，提示脂肪酸氧化失调。重度NAFLD患者的血浆12 - 羟基 - 硬脂酸酯（12HEST）水平高于其他阶段，表明活性氧产生的饱和脂肪酸羟基化在NAFLD的这一严重阶段更为明显。12HEST和PGF2α的血浆水平是诊断NAFLD与非NAFLD的潜在候选生物标志物。总之，通过测量游离PUFA和氧化脂质的血浆水平，可以监测NAFLD的进展，这些氧化脂质表征了不同的NAFLD阶段或代谢综合征患者中是否存在该疾病。
